EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

November 12, 2019

Study Completion Date

November 12, 2019

Conditions
Macular DegenerationWet Macular Degeneration
Interventions
DRUG

Intravitreal aflibercept injection

Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.

Trial Locations (1)

92126

Shiley Eye Center, La Jolla

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

University of California, San Diego

OTHER

NCT02689518 - EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection | Biotech Hunter | Biotech Hunter